# Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT

> **NCT05923814** · PHASE2 · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (estimated)

## Conditions studied

- The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT

## Interventions

- **DRUG:** CD25 prophylaxis

## Key facts

- **NCT ID:** NCT05923814
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-07
- **Primary completion:** 2024-05-07
- **Final completion:** 2024-05-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05923814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05923814, "Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05923814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*